Fig. 1: Inhibition of CPT1 increases oxylipin levels significantly during inflammation in vivo and in peritoneal macrophages.

a, b Plots for individual lipids showing that inhibition of CPT1 enhances oxylipin levels, with a bigger impact during inflammatory challenge with LPS. Wild-type mice (female, 7–9 weeks) were injected i.p. with vehicle (PBS), etomoxir (100 μg), or LPS (1 μg). After 6 h, lavage was harvested and lipids extracted using SPE then analyzed using LC/MS/MS as outlined in Methods. A series of example lipids from 12/15-LOX, COX, and CYP450 are shown (n = 10). c, d Plots for individual lipids showing the impact of etomoxir ± LPS on oxylipin release by peritoneal macrophages in vitro. Peritoneal macrophages were isolated as described in Methods, then cultured in serum-free medium in the presence of etomoxir (25 μM) with/without LPS (100 ng/ml). After 24 h, the supernatant was harvested and lipids extracted using SPE, then analyzed using LC/MS/MS. A series of lipids based on enzymatic origin are shown, n = 3 per sample. For all panels, data are mean ± SEM, one-way ANOVA with Tukey post hoc test, stats are shown for the effect of etomoxir only, where significant. Where no bar is shown no significant difference was seen.